請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55639
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李繼忠(Jih-Jong Lee) | |
dc.contributor.author | Han-Yun Cheng | en |
dc.contributor.author | 鄭涵勻 | zh_TW |
dc.date.accessioned | 2021-06-16T04:14:18Z | - |
dc.date.available | 2020-08-06 | |
dc.date.copyright | 2020-08-06 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-07-29 | |
dc.identifier.citation | Barber LG, Sørenmo KU, Cronin KL, Shofer FS. Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc. 2000;36(5):416-421. Bray J, Polton G. Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection-site sarcoma: results in 21 cats. Vet Comp Oncol. 2016;14(2):147-160. Bregazzi VS, LaRue SM, McNiel E, et al. Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated sarcomas: 25 cases (1995-2000). J Am Vet Med Assoc. 2001;218(4):547-550. Buracco P, Martano M, Morello E, Ratto A. Vaccine-associated-like fibrosarcoma at the site of a deep nonabsorbable suture in a cat. Vet J. 2002;163(1):105-107. Cohen M, Wright JC, Brawner WR, Smith AN, Henderson R, Behrend EN. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). J Am Vet Med Assoc. 2001;219(11):1582-1589. Cronin K, Page RL, Spodnick G, et al. Radiation therapy and surgery for fibrosarcoma in 33 cats. Vet Radiol Ultrasound. 1998;39(1):51-56. Daly MK, Saba CF, Crochik SS, et al. Fibrosarcoma adjacent to the site of microchip implantation in a cat. J Feline Med Surg. 2008;10(2):202-205. Davidson EB, Gregory CR, Kass PH. Surgical excision of soft tissue fibrosarcomas in cats. Vet Surg. 1997;26(4):265-269. Dillon CJ, Mauldin GN, Baer KE. Outcome following surgical removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992-2000). J Am Vet Med Assoc. 2005;227(12):1955-1957. Doddy FD, Glickman LT, Glickman NW, Janovitz EB. Feline fibrosarcomas at vaccination sites and non-vaccination sites. J Comp Pathol. 1996;114(2):165-174. Eckstein C, Guscetti F, Roos M, Martín de las Mulas J, Kaser-Hotz B, Rohrer Bley C. A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma. Vet Comp Oncol. 2009;7(1):54-68. Giudice C, Stefanello D, Sala M, et al. Feline injection-site sarcoma: recurrence, tumour grading and surgical margin status evaluated using the three-dimensional histological technique. Vet J. 2010;186(1):84-88. Hartmann K, Day MJ, Thiry E, et al. Feline injection-site sarcoma: ABCD guidelines on prevention and management. J Feline Med Surg. 2015;17(7):606-613. Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS, Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J Am Vet Med Assoc. 2000;216(1):58-61. Holtermann N, Kiupel M, Hirschberger J. The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. Vet Comp Oncol. 2017;15(2):632-640. Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol. 2004;54(1):25-33. Kobayashi T, Hauck ML, Dodge R, et al. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound. 2002;43(5):473-479. Lachowicz JL, Post GS, Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med. 2005;19(6):860-864. Ladue T, Klein MK. Toxicity criteria of the veterinary radiation therapy oncology group. Vet Radiol Ultrasound. 2001;42(5):475-476. Lawrence J, Saba C, Gogal R, Jr., et al. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Vet Comp Oncol. 2012;10(2):143-154. Liptak JM, Christensen NI. Soft tissue sarcomas. In: Vail DM, Thamm DH, Liptak JM, eds. Withrow MacEwen’s Small Animal Clinical Oncology. 6th ed. St. Louis, Missouri: Elsevier Saunders; 2020:404-431. Madewell BR, Griffey SM, McEntee MC, Leppert VJ, Munn RJ. Feline vaccine-associated fibrosarcoma: an ultrastructural study of 20 tumors (1996-1999). Vet Pathol. 2001;38(2):196-202. Martano M, Morello E, Buracco P. Feline injection-site sarcoma: past, present and future perspectives. Vet J. 2011;188(2):136-141. Martano M, Morello E, Iussich S, Buracco P. A case of feline injection-site sarcoma at the site of cisplatin injections. J Feline Med Surg. 2012;14(10):751-754. Martano M, Morello E, Ughetto M, et al. Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases. Vet J. 2005;170(1):84-90. Mayer MN, Treuil PL, LaRue SM. Radiotherapy and surgery for feline soft tissue sarcoma. Vet Radiol Ultrasound. 2009;50(6):669-672. McLeland SM, Imhoff DJ, Thomas M, Powers BE, Quimby JM. Subcutaneous fluid port-associated soft tissue sarcoma in a cat. J Feline Med Surg. 2013;15(10):917-920. Müller N, Kessler M. Curative-intent radical en bloc resection using a minimum of a 3 cm margin in feline injection-site sarcomas: a retrospective analysis of 131 cases. J Feline Med Surg. 2018;20(6):509-519. Munday JS, Banyay K, Aberdein D, French AF. Development of an injection site sarcoma shortly after meloxicam injection in an unvaccinated cat. J Feline Med Surg. 2011;13(12):988-991. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176-183. Nolan MW, Griffin LR, Custis JT, LaRue SM. Stereotactic body radiation therapy for treatment of injection-site sarcomas in cats: 11 cases (2008-2012). J Am Vet Med Assoc. 2013;243(4):526-531. Phelps HA, Kuntz CA, Milner RJ, Powers BE, Bacon NJ. Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998-2002). J Am Vet Med Assoc. 2011;239(1):97-106. Poirier VJ, Thamm DH, Kurzman ID, et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med. 2002;16(6):726-731. Porcellato I, Menchetti L, Brachelente C, et al. Feline Injection-Site Sarcoma. Vet Pathol. 2017;54(2):204-211. Romanelli G, Marconato L, Olivero D, Massari F, Zini E. Analysis of prognostic factors associated with injection-site sarcomas in cats: 57 cases (2001-2007). J Am Vet Med Assoc. 2008;232(8):1193-1199. Rossi F, Marconato L, Sabattini S, et al. Comparison of definitive-intent finely fractionated and palliative-intent coarsely fractionated radiotherapy as adjuvant treatment of feline microscopic injection-site sarcoma. J Feline Med Surg. 2019;21(2):65-72. Saba CF, Vail DM, Thamm DH. Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma. Vet Comp Oncol. 2012;10(4):283-291. Turek M, Gogal R, Jr., Saba C, et al. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions. Res Vet Sci. 2014;96(2):304-307. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55639 | - |
dc.description.abstract | 由於貓注射部位相關肉瘤具有強烈局部侵犯性,局部腫瘤控制成為重要且具挑戰性的議題,合併放射治療及大範圍手術等多種治療方式可能有較佳的預後。 本回溯性研究目的為比較不同治療方式安排的成效,包含單用手術、單用低分次放射治療以及併用兩者。回溯國立臺灣大學附設動物醫院 2005 年至 2019 年之間的病例,共有 65 隻罹患注射部位相關肉瘤的貓被納入本研究。根據不同的治療方式安排將患貓分為四組,包含手術併用術後低分次放射治療、術前低分次放射治療併用手術、單用低分次放射治療及單用手術。 比較術前低分次放射治療併用手術組及單用低分次放射治療組,腫瘤最大直徑、放射治療總劑量及對於放射治療之反應在兩組間均無顯著差異。中位無疾病進展期亦無顯著差異,分別為 206 天(95% 信賴區間(CI)0–437 天)及 150 天 (95% CI 109–191 天)(P = 0.259)。然而,中位存活時間在術前低分次放射治療併用手術組則顯著較長,分別為687天(95% CI 0–1598天)及248天(95% CI 160—336 天)(P = 0.009)。 比較手術併用術後低分次放射治療組及單用手術組,腫瘤最大直徑、中位無疾病進展期及中位存活時間均無顯著差異。中位無疾病進展期分別為 460 天(95% CI 292–628 天)及 410 天(95% CI 0–910 天)(P = 0.823),中位存活時間分別為 952 天(95% CI 602–1302 天)及 779 天(95% CI 533–1025 天)(P = 0.646),局部腫瘤復發率分別為 44%及 50%。 比較術前及術後使用低分次放射治療的兩組,發現術前放射治療組有顯著較大的腫瘤最大直徑,其為可能影響預後的重要因子,因此無法比較出術前或是術後的低分次放射治療為較佳的治療安排。而在 4 組間比較,單用放射治療的患貓比起其他 3 組有顯著較短的中位存活時間(P < 0.001、P = 0.009 及 P = 0.001)。 總結本研究,在有巨觀團塊且腫瘤直徑較大時,術前低分次放射治療併用手術比起單用低分次放射治療有明顯較佳的腫瘤控制效果。關於術前與術後低分次放射治療在貓注射部位相關肉瘤治療上扮演的角色,未來有待更大規模前瞻性且隨機分組的研究加以證實。 | zh_TW |
dc.description.abstract | Local tumor control of feline injection site-associated sarcoma (FISS) has been a challenging issue due to the locally aggressive behavior. Multimodality therapy, which consisted of radical surgery and radiation therapy (RT) might result in better outcome. The aim of this retrospective study was to compare the efficacy of different local treatment arrangements including either surgery, hypofractionated RT, or in combination. Sixty-five cats diagnosed with FISSs in National Taiwan University Veterinary Hospital from 2005 to 2019 were enrolled retrospectively. Based on the arrangement of treatments, cats were divided into four groups, including adjuvant RT (ART), neoadjuvant RT (NRT), RT alone (RT), and surgery alone (SA). Between the NRT and RT group, no significant difference was noted in tumor diameter, the total dose of radiation therapy, and response to radiation therapy. The median progression-free survival (PFS) was 206 days [95% confidence interval (CI) 0–437 days] for NRT and 150 days [95% CI 109–191 days] for RT alone group (P = 0.259), while the median overall survival time (OST) was significantly longer in the NRT group than that in the RT group (687 days [95% CI 0–1598 days] versus 248 days [95% CI 160–336 days], P = 0.009). Between the ART and SA group, the tumor diameter, median PFS (460 days [95% CI 292–628 days] versus 410 days [95% CI 0–910 days], P = 0.858) and median OST (952 days [95% CI 602–1302 days] versus 779 days [95% CI 533–1025 days], P = 0.646) were not significantly different. The local recurrence rates were 44% and 50% for the ART and SA groups, respectively. Significantly larger tumor size was found in the NRT group compared to the ART group, and therefore became a possible confounding factor. Among all groups, cats in the RT group had significantly shorter median OST than the other groups (P < 0.001, P = 0.009 and P = 0.001). In conclusion, neoadjuvant RT followed by surgery led to a better tumor control than RT alone in patients with large macroscopic disease. A further prospective randomized study was warranted to identify the role of adjuvant and neoadjuvant hypofractionated RT in the management of FISS. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T04:14:18Z (GMT). No. of bitstreams: 1 U0001-2907202014482600.pdf: 1114901 bytes, checksum: 186b82eaf1a5e07302a84e6aa1c0ec08 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 誌謝 i 中文摘要 ii ABSTRACT iv CONTENTS vi LIST OF FIGURES viii LIST OF TABLES x LIST OF ABBREVIATIONS xi Chapter 1 Literature review 1 1.1 Feline injection site-associated sarcoma 1 1.2 Surgery 1 1.3 Radiation therapy 2 1.4 Medical treatment 4 1.5 Prognostic factors 5 Chapter 2 Introduction 6 Chapter 3 Materials and Methods 7 3.1 Patient selection 7 3.2 Tumor staging 7 3.3 Surgical procedures and histologic evaluation 8 3.4 Radiation therapy procedures 8 3.5 Evaluation of treatment response and side effects 9 3.6 Statistical analysis 9 Chapter 4 Result 11 4.1 Demographics 11 4.2 Treatment groups 12 4.2.1 Adjuvant radiation therapy group 12 4.2.2 Neoadjuvant radiation therapy group 14 4.2.3 Radiation therapy alone group 16 4.2.4 Surgery alone group 17 4.3 Comparison of study groups 19 4.3.1 Between four groups 19 4.3.2 Neoadjuvant RT group and RT alone group 20 4.3.3 Adjuvant RT group and surgery alone group 21 4.3.4 Adjuvant RT group and Neoadjuvant RT group 22 4.4 Prognostic factors 23 Chapter 5 Discussion 26 5.1 Efficacy of different therapy arrangements 26 5.1.1 Neoadjuvant RT and RT alone 26 5.1.2 Adjuvant RT and surgery alone 28 5.1.3 Neoadjuvant RT and adjuvant RT 30 5.1.4 Radiation toxicity 31 5.2 Prognostic factors 32 5.3 Limitations 34 Chapter 6 Conclusion 36 Figures 37 Tables 53 REFERENCE 61 | |
dc.language.iso | en | |
dc.title | 使用外科手術及低分次放療在貓注射相關肉瘤之治療安排 | zh_TW |
dc.title | Surgery and Hypofractionated Radiation Therapy Arrangement for Feline Injection Site-associated Sarcoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 季匡華(Kwan-Hwa Chi),王尚麟(Shang-Lin Wang),廖泰慶(Albert Taiching Liao),林辰栖(Chen-Si Lin) | |
dc.subject.keyword | 貓注射部位相關肉瘤,低分次放射治療,手術, | zh_TW |
dc.subject.keyword | Feline injection site-associated sarcoma,Hypofractionated radiation therapy,Surgery, | en |
dc.relation.page | 63 | |
dc.identifier.doi | 10.6342/NTU202002035 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-07-30 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2907202014482600.pdf 目前未授權公開取用 | 1.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。